Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT001 dose-escalation phase I/IIa study in Chinese children with advanced solid tumors and brain tumors
ChiCTR2000031532Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dimethylaminomicheliolide in central nervous system tumor, diffuse intrinsic pontine glioma (DIPG) and Nonhematologic neoplasms (3 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: Incidence and severity of adverse events, Dose-limiting toxicity and 1 more. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
dimethylaminomicheliolide
03
Conditions
central nervous system tumordiffuse intrinsic pontine glioma (DIPG)Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2000031532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031532.